Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.

Hertz, Frederik Boëtius; Andreasen, Minna Rud; Almind, Stine Radmer; Nielsen, Karen Leth; Hansen, Katrine Hartung; Jelsbak, Lotte; Frimodt-Møller, Niels; Schønning, Kristian

Hertz, Frederik Boëtius; Andreasen, Minna Rud; Almind, Stine Radmer; Nielsen, Karen Leth; Hansen, Katrine Hartung; Jelsbak, Lotte; Frimodt-Møller, Niels; Schønning, Kristian.

Afiliación

Hertz FB; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Andreasen MR; Department of Science and Environment, Roskilde University, Roskilde, Denmark; Department of Clinical Microbiology 445, Copenhagen University Hospital, Hvidovre Hospital, Hvidovre, Denmark.
Almind SR; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Nielsen KL; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Hansen KH; Department of Clinical Microbiology 445, Copenhagen University Hospital, Hvidovre Hospital, Hvidovre, Denmark.
Jelsbak L; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Frimodt-Møller N; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Schønning K; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Microbiology 445, Copenhagen University Hospital, Hvidovre Hospital, Hvidovre, Denmark. Electronic address: kristian.schoenning@regionh.dk.

Int J Antimicrob Agents ; 59(4): 106543, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35134504

Asunto(s)

Antígenos CD/metabolismo; Infecciones por Escherichia coli; Proteínas de Neoplasias/metabolismo; Peritonitis; Animales; Antibacterianos/farmacología; Antibacterianos/uso terapéutico; Cefotaxima/farmacología; Cefotaxima/uso terapéutico; Escherichia coli; Infecciones por Escherichia coli/tratamiento farmacológico; Infecciones por Escherichia coli/microbiología; Ratones; Pruebas de Sensibilidad Microbiana; Piperacilina/farmacología; Piperacilina/uso terapéutico; Combinación Piperacilina y Tazobactam/farmacología; Tazobactam/farmacología; Tazobactam/uso terapéutico; beta-Lactamasas/genética

Palabras clave

Antibiotic exposure; Gene expression; MIC; Penicillin/beta-lactamase-inhibitor combinations; Promoter

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Peritonitis / Antígenos CD / Infecciones por Escherichia coli / Proteínas de Neoplasias Límite: Animals Idioma: En Revista: Int J Antimicrob Agents Año: 2022 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google